Loratadine-associated cystoid macular edema: A case report

Yong Tang, Rui Dou, Yuyan Liu, Shiyong Xie, Quanhong Han*

Keywords: Cystoid macular edema Loratadine Optical coherence tomography Histamine

ABSTRACT

Purpose: To report the first known case of bilateral cystoid macular edema in a patient undergoing long-term loratadine treatment.

Observations: A 49-year-old Chinese woman who had been undergoing treatment with loratadine for the past 6 years presented with decreased visual acuity and bilateral cystoid macular edema (CME). Upon cessation of loratadine, macular edema partially resolved, and visual acuity markedly improved. Fundus autofluorescence (FAF), optical coherence tomography (OCT), and fluorescence fundus angiography (FFA) were used to document the severity of CME and its subsequent resolution after cessation of loratadine therapy.

Conclusions and Importance: Long-term use of loratadine might cause CME that partially resolves with discontinuation of the drug. The pathophysiology of drug-induced CME without leakage remains unclear. Dysfunction of histamine receptor1-expressed retinal neurons and the associated signal transduction, toxicity to Müller cells or RPE cells with subsequent intracellular fluid accumulation, and subclinical damage to the blood-retina barrier leading to leakage of extracellular fluid, have been proposed.

1. Introduction

Loratadine, a selective inverse agonist of peripheral histamine H1 receptors, is used to relieve the symptoms associated with allergic rhinitis and seasonal allergic conjunctivitis. It is devoid of significant central and autonomic nervous system effects, and extensive clinical investigations have proven the safety and efficacy of loratadine in the treatment of allergic symptoms. To date, at the recommended doses, the ocular side effects of loratadine have been reported only on ocular drying. In the present report, we describe the first case of bilateral cystoid macular edema (CME) in a Chinese woman with allergic rhinitis who underwent loratadine therapy for six years, before presenting to our hospital.

2. Case report

A 49-year-old Chinese woman complained of gradually blurring vision in her right eye for the past one year. She had been diagnosed with allergic rhinitis eight years ago and received loratadine 5 mg per day routinely for the past six years. The patient had no history of diabetes, hypertension, or ocular diseases, and had not yet undergone any intraocular surgery. Her family history was negative for congenital X-linked retinoschisis, Goldmann-Favre syndrome, and retinitis pigmentosa. She was not taking any other drugs and had no conditions associated with macular damage.

At the initial ophthalmologic examination, the best-corrected visual acuity was 3/20 OD and 8/20 OS, and intraocular pressure was 18 mmHg OD and 17 mmHg OS. The anterior segment examination was unremarkable, except for incipient nuclear sclerotic cataract. Pupils, extraocular motility, and confrontation visual fields were within normal limits. Funduscopy revealed healthy optic nerves and vessels along with a normal peripheral fundus, aside from absence of definite foveal light reflex in either eye. Fluorescein angiograms (Fig. 1A and B; Optomap 200Tx, Optos, UK). Posterior vitreous detachment was noted bilaterally with no evidence of vitreoretinal interface abnormalities. Fundus autofluorescence (FAF) (Fig. 1C-F) revealed bilateral stellate hypofluorescence in the fovea. Spectralis HRA + OCT, Heidelberg Engineering GmbH, Heidelberg, Germany) revealed normal filling of the choroidal and retinal vessels and an intact parafoveal capillary net. The late frames of the angiograms did not show any significant vascular leakage. RTVue optical coherence tomography (OCT) (Optovue Inc., Fremont, CA) revealed bilateral CME.
with cystoid changes in the outer plexiform and inner nuclear layers (Fig. 1K-N).

In the present case, chronic progression of signs and symptoms with loratadine and bilateral CME was observed. To the best of our knowledge, this is the first case of bilateral CME associated with loratadine therapy. Considering that the patient did not take any other drugs or present with other medical conditions associated with macular edema, CME was thought to be secondary to loratadine use. After consultation with an otolaryngologist, loratadine therapy was discontinued.

Four weeks after the initial visit, the patient was symptomatically better and her BCVA improved to 12/20 OD and 18/20 OS, with bilateral structural improvement of macular edema (Fig. 2 B,F).

At 2-month follow-up, her BCVA had further improved to 16/20 OD and 20/20 OS. CME partially resolved in OD (Fig. 2C) and markedly improved in OS (Fig. 2G).

At 6-month follow-up, BCVA was 18/20 OD and 20/20 OS. There were some residual macular cystoid spaces in OD (Fig. 2D). CME was fully resolved with complete restoration of visual acuity and foveal structure in OS (Fig. 2H). with some residual macular cystoid spaces in OD (Fig. 2D).

3. Discussion

Drug-induced CME can be caused by various drugs such as taxanes, acitretin, tamoxifen, niacin, interferon, fingolimod, prostaglandin, epinephrine, and timolol among others. However, systemic anti-histamines- or anti-histamine eye drops-induced CME has not yet been reported. To date, this is the first case of bilateral CME associated with loratadine therapy.

CME is characterized by abnormal thickening of the retina associated with excess fluid accumulation within the macular retina following disruption of the blood-retinal barrier. Furthermore, Müller cells play an important role in macular dehydration via metabolic pumps. These conditions are induced by microvascular occlusion or underlying inflammatory disease.

The typical fluorescein angiographic appearance of CME consists of small focal leaks that increase in size and intensity early on, resulting in late pooling and a characteristic flower-petal pattern with or without leakage surrounding the optic nerve. While for drug-induced CME, several papers have reported that CME was not observed to be associated with leakage on fluorescein angiography. Therefore, the mechanisms of drug-induced CME may differ from those of microvascular occlusion or inflammatory disease. The characteristics of drug-induced CME are: (1) often bilateral, (2) no leakage on fluorescence fundus angiography.

Fig. 1. Multimodal images of both eyes (OD/OS) at initial examination. (A, B) Retinal blood vessels were normal with no edema, bleeding or exudation as observed in wide-field fundus photograph. No definite fovea reflections bilaterally. (C, E) BAF reveals stellate appearance of the fovea bilaterally with no evidence of posterior segment inflammation or optic disc hyperfluorescence. (D, F) IR AF shows abnormal areas of hyporeflectance in the central macula. (G–J) FFA shows stellate appearance of the fovea bilaterally with no evidence of vascular leakage or optic disc hyperfluorescence. (K–N) OCT shows intraretinal cystic changes, mainly affecting the outer plexiform layer (OPL) and outer nuclear layer (ONL) with ellipsoid zone disruption. BAF, Blue-light Fundus autofluorescence; IR AF, Near-infrared autofluorescence; FFA, fundus fluorescence angiography; OCT, ocular contrast tomography. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
angiography (FFA), (3) a larger cystic space in the outer rather than the inner layer of the retina on OCT scans, and (4) spontaneous resolution and improvement of visual acuity after discontinuation of the causative drug.

Several questions need to be answered before we can deduce that loratadine might be a potential cause of drug-induced CME in this patient:

1) Whether loratadine can pass the blood-retinal barrier (BRB)?
2) Whether there are Histamine (HA) neurons in the retina?
3) Whether there are histamine receptors in the retina?

As a second-generation antihistamine, loratadine is a reverse agonist of peripheral histamine receptor 1 (HR1). The sedating effect of first-generation H1-antihistamines has been associated with the penetration of the blood-brain barrier (BBB) and lack of efflux by P-glycoprotein (Pgp). Some second-generation antihistamines, such as terfenadine and loratadine, can cause dose-dependent sedation, indicating their potential to cross the BBB. Lack of sedative effects on the central nervous system (CNS) and restricted BBB penetration have been proposed to arise from Pgp-mediated efflux. Given the structural similarities between the BBB and BRB, there might be potential pathways for loratadine to gain access to the retina. However, little is known about the penetration of loratadine across the BRB.

Histamine (HA), a small molecule synthesized from the amino acid histidine, is associated with allergy, inflammation, and T-cell regulation. In the brain, histamine is stored in mast cells and other non-neuronal cells and acts as a neurotransmitter. The firing patterns of HA neurons show circadian rhythms, and HA is known to promote arousal, which is consistent with the drowsiness effects of antihistamines. HA neuron cell bodies lie in the tuberomammillary (TM) nucleus of the hypothalamus, and these neurons send projections throughout the CNS, particularly to the cerebral cortex, retina, amygdala, basal ganglia, hippocampus, thalamus, and spinal cord. Mast cells, which are another possible source of histamine, are not present in the retina.

Projected from the TM nucleus in the hypothalamus, the functions of retinopetal axons in mammalian retina is not well understood. HA has been localized to retinopetal axons in the guinea pig, monkey, and rat retinas. The axons of these neurons enter the retina through the optic disc, run through the optic fiber layer, and terminate in the inner plexiform layer (IPL).

Using immunofluorescence, previous research has shown that HR1 is expressed by horizontal cells and a small number of amacrine cells. HR2 is closely associated with the synaptic ribbons inside the cone pedicles. HR3 was located on the tips of the ON bipolar cell dendrites. All three major targets of histamine are distributed in the outer plexiform layer, while retinopetal axons containing histamine terminate in the inner plexiform layer. These findings suggest that the effects of histamine released by the retinopetal axons in the primate retina are mediated by volume transmission. Inhibition by an HR antagonist might interfere with signal transduction or cellular metabolism of related retinal neurons and lead to subsequent intracellular edema. Other possibilities have been proposed to explain the etiology of cystic changes in the macula that develop in loratadine-related maculopathy. First, loratadine has direct toxic effects on Müller cells without disrupting the BRB. Changes in cellular metabolism cause intracellular fluid retention following cessation of loratadine therapy, there is partial or complete recovery of Müller cells and their normal function, accounting for the resolution of CME.

Retinal pigment epithelium (RPE) maintains retinal attachment by actively pumping water and electrolytes out of the subretinal space. Earlier research in 1991 reported that histamine stimulates both RPE phosphoinositide turnover and intracellular Ca\(^{2+}\) release through HR1. Recently, an in vitro study of a cell line from the human RPE (hRPE-YC) showed concentration-dependent increases in cytosolic Ca\(^{2+}\) concentrations after treatment with histamine and complete suppression of histamine-induced Ca\(^{2+}\) mobilization by the HR1 antagonist d-chlorpheniramine in hRPE-YC cells. However, substantial in vivo evidence is lacking to prove the hypothesis that interference of RPE pump function is involved in intraretinal water retention following long-term use of loratadine.

Other hypothesis suggests that subclinical disruption of the normal BRB might be caused by molecules with a molecular weight lower than that of fluorescein, which leads to fluid accumulation in the intracellular or extracellular space with no leakage on FFA. Nevertheless, histamine HR1 and HR2 stimulation of retinal vessels mediates BRB permeability. Inhibition of histamine activity with HR1 or HR2 antagonists returns BRB leakage to control levels despite uncontrolled diabetes.
Therefore, damage to the BRB might not be a possible mechanism for loratadine-related CME in this patient. As a nonprescription drug, the recommended dosing of loratadine for allergic rhinitis or conjunctivitis is 10 mg once daily or 5 mg twice daily, with no definitive limit in the course of treatment, and additional cases developing CME must be studied to establish a real association. When examining patients with macular edema, a history of drug intake should be considered, especially when there is no leakage observed on FFA. Further research into the mechanisms of the ocular adverse events resulting from loratadine might be helpful in highlighting this association.

Funding

This study was funded by Tianjin Key Medical Discipline (Specialty) Construction Project.

Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Patient consent

Consent for publication of this case report was obtained from the patient in writing.

Declaration of competing interest

All authors declare no conflicts of interest.

Acknowledgements

None.

References

1. Roman LJ, Danzig MR. Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy. Spring 1993;11(1):89-110.
2. Welch D, Ousler 3rd GW, Nally LA, Abelson MB, Wilcox KA. Ocular drying associated with oral antihistamines (loratadine) in the normal population—an evaluation of exaggerated dose effect. Adv Exp Med Biol. 2002;506(Pt B):1051-1055.
3. Ousler 3rd George W, Andrew Workman D, Torkilden Gail L. An open-label, investigator-masked, crossover study of the ocular drying effects of Two antihistamines, topical epinephrine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Therap. 2007 Apr;29(4):611-616.
4. Teitelbaum Bruce A, Tresley David J. Cystic maculopathy with normal capillary permeability secondary to doxetaxel. Optom Vis Sci. 2003 Apr;80(4):277-279.
5. Yap J, Buller A. Cystoid macular edema associated with acitretin. Dig J Ophthalmol. 2013 Dec 30;19(4):56-58.
6. Zafeiropoulos P, Nanas P, Tsikouli E, Stefaniotou M. Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature. Case Rep Ophthalmol. 2014 Dec 10;5(3):451-454.
7. Domanico Daniela, Carnevale Carmela, Fraggiotta Serena, Verbovchisi Francesca, Altimari Simona, Maria Vingolo Enzo. Cystoid macular edema induced by low doses of nicotinic Acid. Case Rep Ophthalmol Med. 2013;2013:713061.
8. Pul Refkà, Osmanovic Alma, Schmidtzieg Holger, et al. Fingolimod associated bilateral cystoid macular edema-wait and see? Case Reports Int J Mol Sci. 2016 Dec 14;17(12):2106.
9. E Makri Olga, Georgalas Ilia, Georgakopoulos Constantine D. Drug-induced macular edema. Drugs. 2013 Jun;73(8):798-802.
10. Yokoe Takamichi, Fukada Ippei, Kobayashi Kokoro, et al. Cystoid macular edema during treatment with paclitaxel and bevacizumab in a patient with metastatic breast cancer: a case report and literature review. Case Rep Oncol. 2017 Jul 11;10(2):605-612.
11. Ronos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol. 2008;2:919-930.
12. Rao Rajesh C, Choudhry Netan. Cystoid macular edema associated with chemotherapy. CMAJ (Can Med Assoc J). 2016 Feb 16;188(3):216.
13. Rahman HT, Yeh S, Bergstrom CS. Cystoid macular edema without leakage secondary to paclitaxel (Abraxane®): clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Therapeut. 2013;29:360-362.
14. Domanico D, Carnevale C, Fraggiotta S, Verbovchisi F, Altimari S, Vingolo EM. Cystoid macular edema induced by low doses of nicotinic Acid. Case Rep Ophthalmol Med. 2013;2013:713061.
15. Bassi E, Loizzi V, Furino C, et al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol. 2017 Aug;7(2):285-287.
16. Chihtry M, Reichol A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target. 2001 Jun;9(3):223-228.
17. McDonald Kathleen, Trick Leonne, Boyle Julia. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmac. 2008 Oct;23(7):555-570.
18. Chen Cuiping, Hanson Elizabeth, Watson John W, Lee Jae S. P-glycoprotein limits the brain penetration of nosedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-318.
19. Dale H, Laidlaw P. The physiological action of β-iminazolylythylamine. J Physiol. 1910;41:318-344.
20. Haas H, Sergeeva O, Selbach O. Histamine in the nervous system. Physiol Rev. 2008; 88:1183-1241.
21. Schwartz J-C. Histamine as a transmitter in brain. Life Sci. 1974;17:503-518.
22. Mayeama K, Watanabe T, Yamatodani A, Taguchi Y, Rambe H, Wada H. Effect of alpha-fluoroornethylhistidine on the histamine content of the brain of w/w mice devoid of mast cells: turnover of brain histamine. J Neurochem. 1983;41:128-134.
23. Mayeama K, Watanabe T, Yamatodani A, Taguchi Y, Rambe H, Wada H. Effect of alpha-fluoroornethylhistidine onthe histamine content of the brain of w/w mice devoid of mast cells: turnover of brain histamine. J Neurochem. 1983;41:128-134.
24. Best J, Nijhout HF, Samarasekaye S, Hashemi P, Reed M. A mathematical model for histamine synthesis, release, and control in varicosities. Theor Biol Med Model. 2017 Dec 12;14(1):24.
25. Arakitsinsen MS, Panula P. The histaminergic system in the Guinea pig central nervous system: an immunocytochemical mapping study using an antiseraum against histamine. J Comp Neurol. 1988;273:163-186.
26. Gastrin JJ, O’Brien SJ, Larsen NB, Marshall DW. Histamine immunoreactive axons in the macaque retina. Invest Ophthalmol Vis Sci. 1999;40:487-495.
27. Gastrin JJ, Barber AJ, Khin SA, McMill CS, Gardner TW, Marshall DW. Abnormal centrifugal axons in streptozotocin-diabetic rat retinas. Invest Ophthalmol Vis Sci. 2001;42:2679–2685.
28. Gastrin JJ, Barber AJ, Lister IA, Vardi N, Marshall DW. Histamine receptors in mammalian retinas. J Comp Neurol. 2006 Apr 20;495(6):658-667.
29. Vila Alejandro, Satoh Hiromasa, Rangel Carolina, et al. Histamine receptors of cones and horizontal cells in Old World monkey retinas. J Comp Neurol. 2012 Feb 15;520(3):528-543.
30. Feldman EL, Randolph AE, Johnston GC, DelMonte MA, Greene DA. Receptor-efflux transport sites, histamine H1-receptors, in bovine retinal blood vessels. J Physiol. 2001 Jun;538(3):855-872.
31. Morioka E, Kanda Y, Koizumi H, Miyamoto T, Ikeda M. Histamine regulates centrifugal axons in streptozotocin-diabetic rat retinas. Invest Ophthalmol Vis Sci. 2002;43:2679–2685.
32. Gastrin JJ, Barber AJ. Centrifugal histaminergic projections and horizontal cells in the retina. Arch Ophthalmol. 1995;113(2):134.
33. Fredman EL, Randolph AE, Johnston GC, DelMonte MA, Greene DA. Receptor-efflux transport sites, histamine H1-receptors, in bovine retinal blood vessels. J Physiol. 2001 Jun;538(3):855-872.
34. Sawai S, Fukuda H, Fukuda M, Wang NP, Wada H, Manabe R. [3H]mepyramine binding sites, histamine H1-receptors, in bovine retinal blood vessels. Curr Eye Res. 1991 Aug;10(8):713-718.
35. Hollis J, Sibley K, Butler C, Campos MJ, Gardner TW. Astemizole reduces blood-retinal barrier leakage in experimental diabetes. J Diabet Complicat. Dec 1992;6(4):230-235.
36. Gardner TW, Eller AW, Friberg TR, Dario AN, Hollis TM. Antihistamines reduce blood-retinal barrier permeability in type 1 (insulin-dependent) diabetic patients with nonproliferative retinopathy. A pilot study. Retina. 1995;15(2):134-140.